Skip to main content

Security report for biogen.tw

Biogen · Healthcare · Taiwan

Low risk. 2 critical or high findings in Email security and SSL/TLS.

Security score

78/100

Risk levelLow

0–100, higher is better. How it is calculated

Biogen Taiwan operates as a regional branch of the global biotechnology leader Biogen, specializing in innovative drug development for complex neurological and rare diseases. The website reflects a mature digital presence with a focus on corporate branding, patient and healthcare professional engagement, and compliance with privacy regulations. The technical infrastructure leverages Adobe Experience Manager CMS, modern JavaScript libraries, and integrates Google Analytics and Cookiebot for analytics and consent management. Security posture is strong with HTTPS, secure cookies, and consent mechanisms, though explicit security policies and incident response details are not published. Overall, the site is professional, trustworthy, and well-optimized for its target audience in Taiwan.

Scanned

NIS2 and GDPR posture

GDPR outside view
83/ 100 · Low
Checks completed
7of 7

NIS2 Art. 21(2)

  1. (a) Risk analysis and security policies: Not visible from outside
  2. (b) Incident handling: One indicator
  3. (c) Business continuity, backups and crisis management: Not visible from outside
  4. (d) Supply chain security: Not visible from outside
  5. (e) Secure acquisition, development and maintenance, including vulnerability handling: Partly checked
  6. (f) Assessing the effectiveness of security measures: Not visible from outside
  7. (g) Cyber hygiene and security training: Not visible from outside
  8. (h) Cryptography and encryption: Partly checked
  9. (i) HR security, access control and asset management: One indicator
  10. (j) Multi-factor authentication and secured communications: Not visible from outside

This scan rated NIS2 with an earlier keyword method that is no longer shown; rescan for the per-article view. Risk management, continuity, supply chain, training, MFA, management oversight (Art. 20) and incident reporting (Art. 23) need internal evidence, and Guard cannot tell whether NIS2 applies to this organisation.

GDPR is indicative only, based on publicly visible signals: Articles 7, 12, 13 and 32 of Regulation (EU) 2016/679 and Article 5(3) of the ePrivacy Directive. Not a certification or legal assessment.

Priority findings

2 findings rated critical or high. Fix these first.

  1. Email security

    SPF, DKIM and DMARC stop others sending email that looks like it comes from your domain, a common route to phishing and invoice fraud.

    • Critical

      No email authentication configured

      Domain is vulnerable to email spoofing

      What to do: Implement SPF, DKIM, and DMARC immediately

  2. SSL/TLS

    TLS encrypts the connection and proves the site is really yours. Weak or expiring certificates trigger browser warnings and put traffic at risk.

    • High

      Weak Protocols Supported

      Server supports weak protocols: TLSv1.1

      What to do: Disable TLS 1.0, TLS 1.1, and all SSL versions

      • CWE-327
      • OWASP A04:2025
      • ASVS V12.1.1

Need hands-on remediation? Email guard@offseq.com

Keep watching biogen.tw

This scan found 19 issues across 6 checks. Monitoring re-runs those checks daily, emails you when something material changes and records each fix, so you can show progress.

Daily monitoring

Recommended

€25per month

  • TLS certificates and expiry
  • DNS records
  • SPF, DKIM and DMARC
  • Security headers
  • GDPR and NIS2 posture
  • Exposed services
  • Third-party trackers
  • Security score drift

Email alerts on material changes and an exportable JSON history of every change.

Billed monthly to your card. Cancel anytime. The full timeline opens with your unlock code.

Full report

€39.90one-time

  • The complete analysis as a PDF you can cite
  • Email delivery with an unlock code
  • Lifetime access to this report

Prices incl. 21% VAT. Secure checkout by Mollie; sold by SEQ SIA, Latvia.

Results by check

Each check with its score, findings and the evidence it collected.

How this score is calculated

The security score runs 0–100, higher is better. It is the plain average of the security checks that completed in this scan, each counted equally. A check that could not run is left out: it counts neither as a pass nor as a fail.

Counted in this score

SSL/TLS
62
Security headers
95
Email security
60
DNS health
70
Network security
100
GDPR outside view
83
Average
78

Not counted

  • NIS2 outside view: Re-weights evidence from the TLS, email, DNS, network and hygiene checks, so counting it would count that evidence twice. Shown on its own.
  • OffSeq Observations: An AI reading of the site, useful context but not reproducible evidence. Shown on its own.

Findings that cap the score at 49

Each of these is serious on its own, so while any is present the site cannot rate better than high risk, however good the other checks are.

  • The certificate is not trusted by browsers
  • The website is not served over HTTPS
  • A database, remote desktop, file-sharing or Telnet service is reachable from the internet
  • The page loads a script from a compromised source
  • The domain registration has expired
  • SPF authorises every server to send mail as the domain

Partial scans

When the site blocks Guard or most checks cannot run, the score covers only the checks that ran (usually DNS and email), is capped at 75 and is shown as partial, without a risk level.

Risk levels

  • Critical0–25
  • High26–49
  • Medium50–75
  • Low76–100

Technical appendix

Business context, site observations and technical notes gathered during the scan, and the standards behind each reference.

Business context

Business profile

Biogen holds a strong market position as a global biotechnology enterprise with a focus on neurological and rare diseases. The Taiwan site supports regional engagement with localized content and language. The business model centers on pharmaceutical R&D and commercialization. The company maintains a broad partnership ecosystem with multiple country-specific domains. The website's content and structure support patient education, corporate responsibility, and career opportunities, indicating a comprehensive approach to stakeholder engagement. The absence of direct contact emails or phone numbers suggests a preference for controlled communication channels via contact forms.

Security posture

The website demonstrates a solid security foundation with HTTPS enforcement, HttpOnly and Secure cookie flags, and a robust cookie consent mechanism via Cookiebot. No critical vulnerabilities or exposed sensitive data were detected. However, the lack of published security policies, incident response procedures, or vulnerability disclosure programs indicates room for improvement in transparency and readiness. The site uses third-party analytics and marketing tools responsibly with user consent. Overall, the security posture is good but could benefit from enhanced documentation and incident communication channels.

Recommendations

  1. Publish a dedicated security policy and incident response page to improve transparency and user trust.
  2. Implement a vulnerability disclosure program or security.txt file to facilitate responsible reporting.
  3. Enhance accessibility features to meet international standards and improve user experience for all visitors.
  4. Regularly review and update third-party scripts and libraries to mitigate potential vulnerabilities.
  5. Consider providing direct contact information for a Data Protection Officer or privacy contact to strengthen GDPR compliance.
Site observations

Automated reading of the public site. Ratings are indicative.

Business

Company
Biogen
Description
百健（Biogen）成立於1978年，為全球領先的生技公司，專注於研發創新藥物，涵蓋多發性硬化症、脊髓性肌肉萎縮症、阿茲海默症等嚴重疾病，致力於用科學造福人群，推動健康、永續與公平的世界。
Key services
創新藥物研發, 疾病治療方案, 科學研究與合作
Content quality
good
Branding
consistent

Technology

Stack
jQuery 3.6.4, Adobe Helix RUM, Cookiebot, Google Tag Manager, Google Analytics
Frameworks
Adobe Experience Manager (AEM)
Platforms
Web
Performance
moderate
Mobile
good
Accessibility
basic
SEO
good

Security

Observed score
85/100
Good practices seen
  • Use of HttpOnly and Secure flags on cookies
  • Cookie consent mechanism implemented
  • No exposed sensitive data in HTML

Analytics and tracking

Services
Google Analytics
Tracking level
moderate
Privacy practices
good

Advertising

Ad networks
Google
Tracking pixels
Cookiebot session tracker
Marketing tools
Cookiebot
Transparency
good

Site quality

Design
good
User experience
good
Content relevance
good
Navigation
good
Professionalism
good
Trustworthiness
high

Key observations

  1. Website is fully accessible with no blocking or WAF challenges.
  2. Content is professionally presented in Traditional Chinese targeting Taiwan users.
  3. Comprehensive cookie consent mechanism implemented with Cookiebot.
  4. Multiple social media channels linked for corporate presence.
  5. No direct email or phone contact found on homepage; contact form available.
  6. No explicit security or incident response policies published.
  7. Use of modern web technologies and Adobe Experience Manager CMS.
  8. Strong branding consistency and clear navigation structure.
  9. No suspicious or malicious content detected.
Technical notes

Notes

The website is built on Adobe Experience Manager CMS, utilizing modern JavaScript libraries such as jQuery 3.6.4 and Adobe Helix RUM for performance monitoring. Cookiebot manages cookie consent, integrated with Google Tag Manager and Google Analytics for tracking and marketing. Hosting appears to leverage AWS infrastructure, inferred from load balancing cookies. The site is mobile-optimized with responsive design and includes SEO best practices such as meta tags and Open Graph data. Performance is moderate, with potential for optimization in loading speed and accessibility compliance. The technical stack is modern and well-maintained, supporting a professional corporate presence.
Standards and sources

Reference chips under each finding point to the standard, regulation or specification the finding relates to. They are taken from the official datasets below and mapped conservatively: a finding with no defensible link shows none. NIS2 and GDPR references mark where a finding is relevant evidence, not a compliance verdict. Implementing Regulation (EU) 2024/2690 binds digital infrastructure and digital service providers; for other entities it is the most detailed public reading of the Article 21 measures. WCAG, EN 301 549, European Accessibility Act and Web Accessibility Directive references name the requirement an automated accessibility rule relates to; they are not a conformance verdict.

Retrieved 2026-10-25

Reviews of this site

Share your experience with biogen.tw. Every review is verified by email and published after moderation.

Overall rating
Select a rating
4000 characters remaining

We’ll email you to confirm your review and keep your details private.

Community rating

No published reviews yet. Be the first to review biogen.tw.

Feedback on this report

Rate this report, add an optional comment, and tell us if you want a security specialist to follow up.

Overall report quality
Select a rating
2000 characters remaining

We only use your feedback to improve Guard reports. Contact details are never shared.